Johnson & Johnson Will Unveil New Rivaroxaban Results on Monday

November 12, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Wall Street Journal -- Johnson & Johnson sat out the blockbuster heart-drug era when cholesterol-lowering statins and blood-pressure pills fueled years of double-digit earnings growth in the pharmaceutical industry.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase 2

Johnson & Johnson Family of Companies